EIP Pharma has conducted neﬂamapimod preclinical studies in animal models. In these models, neﬂamapimod improved neurological outcomes, supporting its use to treat neurological disorders in human patients.
In aged rats with identiﬁed cognitive deﬁcit, neﬂamapimod improved cognitive performance (p=0.007), as assessed in a maze test. The aged rat model was chosen to evaluate neﬂamapimod because the cognitive deﬁcits in that model are due to inﬂammation-induced synaptic dysfunction.
Neﬂamapimod was also studied in a rat stroke model. Neﬂamapimod administered for a duration of six weeks after the stroke led to multiple improved parameters of neurologic function compared to control (p < 0.001 for each of global neurologic scores, motor- and sensory-speciﬁc tests). Recovery after stroke is largely dependent on neuronal and synaptic plasticity, thus these results support our hypothesis that neﬂamapimod can reverse synaptic damage.
"Neflamapimod treatment showed improvement in memory tests that assess immediate and delayed recall in two phase 2a studies, strongly suggestive of reversal of synaptic dysfunction. With the demonstration of proof-of-mechanism and the definition of an optimal dose, neflamapimod is well positioned to demonstrate proof-of-concept on clinical cognitive endpoints in a subsequent study in patients with early Alzheimer's disease."